Clinical effect of Levosimendan and Qiliqiangxin Capsule in congestive heart failure and influence in serum levels of NT-proBNP and Hcy / 药物评价研究

ABSTRACT

Objective To investigate the clinical effect of Levosimendan and Qiliqiangxin Capsule in congestive heart failure and influence in serum levels of NT-proBNP and Hcy.Methods 92 cases of patients with congestive heart failure in our hospital from January 2014 to June 2016 were selected and divided into observation group and control group,46 cases in each group.Patients in the control group were treated with Levosimendan on the basis of conventional treatment,and the observation group were treated with Levosimendan and Qiliqiangxin Capsule.Compared the clinical effect,safety,and the change of serum levels of NT-proBNP and Hey before and after treatment.Results The total effective rate of observation group were higher than control group,but the difference was no significant.After treatment,the left ventricular ejection fraction (LVEF),stroke volume (SV) in two groups were significantly higher than that before treatment,the left ventricular end diastolic diameter (LVEDD) were significantly lower than before treatment (P ＜ 0.05);and the LVEF and SV of the observation group were significantly higher than the control group,LVEDD was significantly lower than the control group (P ＜ 0.05).After treatment,serum levels of NT-proBNP and Hey of two groups were significantly better than before (P ＜ 0.05),and the observation group were better than control group (P ＜ 0.05).The difference in the adverse reaction rate was no significant.Conclusion The clinical curative effect of Levosimendan and Qiliqiangxin Capsule in congestive heart failure is distinct,which can effectively improve the clinical symptoms of patients,the cardiac function,serum levels of NT-proBNP and Hcy.